Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The product will be launched by NATCO's commercial partner Viatris.
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The integration and transition of the brands are expected to be completed by June 2022.
Subscribe To Our Newsletter & Stay Updated
